| ID | 1301 |
| Name of the vaccine | HEXAVAC |
| Microbe | Bacteria |
| Disease name | Tetanus (Lock Jaw) |
| Name of bacteria | Clostridium tetani |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 8 to 15 weeks |
| Description of the vaccine | DTPa-HBV-IPV-Hib vaccine. |
| Name of the manufacturer | GlaxoSmithKline |
| Name of the manufacturing country | Finland, Italy, Sweden |
| Year of manufacture | 2005 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses at 3, 5 and 11-12 months. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | NA |
| Export | Marketing-authorisation holder : Sanofi Pasteur MSD, SNC |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For pertussis, diphtheria, hepatitis B, Haemophilus influenzae type b and poliomyelitis. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination (3 doses) |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01457547 |
| Reference | https://www.ema.europa.eu/en/medicines/human/EPAR/hexavac |
| Other name | NA |
| Additional Links | NA
|